Literature DB >> 35923131

DFNA5 inhibits colorectal cancer proliferation by suppressing the mTORC1/2 signaling pathways via upregulation of DEPTOR.

Jing Guo1, Junhui Yu1, Mingchao Mu1, Zilu Chen1, Zhengshui Xu1, Chenye Zhao1, Kui Yang1, Jianbao Zheng1, Xiao Qin2, Wei Zhao1, Xuejun Sun1.   

Abstract

The human deafness, autosomal dominant 5 gene (DFNA5), a newly discovered executor of pyroptosis, has been strongly implicated in the tumorigenesis of several human cancers. However, an understanding of the functional role of DFNA5 in the development and progression of colorectal cancer (CRC) is limited. In this study, we demonstrated that DFNA5 was downregulated in CRC tissues. Ectopic expression of DFNA5 inhibited tumor cell growth in vitro, retarded tumor formation in vivo, and blocked a cell-cycle transition from the G0/G1 to the S phase, whereas a DFNA5 knockdown promoted cell proliferation. Western blotting showed that the levels of cell cycle-related proteins, including cyclin D1, cyclin E, CDK2, and p21, were accordingly altered upon DFNA5 overexpression or DFNA5 knockdown. Mechanistic studies indicated that DFNA5 exerted its tumor suppressor functions by antagonizing mTORC1/2 signaling via upregulation of DEPTOR. In addition, blockage of mTORC1/2 signaling by Torin-1 abolished the accelerative proliferation by DFNA5 knockdown. In conclusion, these results indicated that DFNA5 inhibits the proliferation and tumor formation of colon cancer cells by suppressing mTORC1/2 signaling.

Entities:  

Keywords:  DEPTOR; DFNA5; cell cycle; colorectal cancer; mTORC1/2; proliferation

Mesh:

Substances:

Year:  2022        PMID: 35923131      PMCID: PMC9518992          DOI: 10.1080/15384101.2022.2088570

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   5.173


  47 in total

Review 1.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

2.  The expression and regulation of DFNA5 in human hepatocellular carcinoma DFNA5 in hepatocellular carcinoma.

Authors:  Cong-Jun Wang; Lin Tang; Dong-Wei Shen; Chao Wang; Qiong-Ying Yuan; Wei Gao; Yong-Kun Wang; Rong-Hua Xu; Hui Zhang
Journal:  Mol Biol Rep       Date:  2013-10-24       Impact factor: 2.316

3.  Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer.

Authors:  Kimishige Akino; Minoru Toyota; Hiromu Suzuki; Takashi Imai; Reo Maruyama; Masanobu Kusano; Noriko Nishikawa; Yoshiyuki Watanabe; Yasushi Sasaki; Tamaki Abe; Eiichiro Yamamoto; Isao Tarasawa; Tomoko Sonoda; Mitsuru Mori; Kohzoh Imai; Yasuhisa Shinomura; Takashi Tokino
Journal:  Cancer Sci       Date:  2007-01       Impact factor: 6.716

4.  Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin.

Authors:  Yupeng Wang; Wenqing Gao; Xuyan Shi; Jingjin Ding; Wang Liu; Huabin He; Kun Wang; Feng Shao
Journal:  Nature       Date:  2017-05-01       Impact factor: 49.962

5.  Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer.

Authors:  Myoung Sook Kim; Cinthia Lebron; Jatin K Nagpal; Young Kwang Chae; Xiaofei Chang; Yiping Huang; Tony Chuang; Keishi Yamashita; Barry Trink; Edward A Ratovitski; Joseph A Califano; David Sidransky
Journal:  Biochem Biophys Res Commun       Date:  2008-03-17       Impact factor: 3.575

6.  Localization of a gene for non-syndromic hearing loss (DFNA5) to chromosome 7p15.

Authors:  G van Camp; P Coucke; W Balemans; D van Velzen; C van de Bilt; L van Laer; R J Smith; K Fukushima; G W Padberg; R R Frants
Journal:  Hum Mol Genet       Date:  1995-11       Impact factor: 6.150

7.  Gasdermin E permits interleukin-1 beta release in distinct sublytic and pyroptotic phases.

Authors:  Bowen Zhou; Derek W Abbott
Journal:  Cell Rep       Date:  2021-04-13       Impact factor: 9.423

Review 8.  Targeting PI3K/Akt/mTOR Signaling in Cancer.

Authors:  Camillo Porta; Chiara Paglino; Alessandra Mosca
Journal:  Front Oncol       Date:  2014-04-14       Impact factor: 6.244

9.  Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells.

Authors:  Junhui Yu; Shan Li; Jie Qi; Zilu Chen; Yunhua Wu; Jing Guo; Kai Wang; Xuejun Sun; Jianbao Zheng
Journal:  Cell Death Dis       Date:  2019-02-25       Impact factor: 8.469

10.  Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.

Authors:  Morris E Feldman; Beth Apsel; Aino Uotila; Robbie Loewith; Zachary A Knight; Davide Ruggero; Kevan M Shokat
Journal:  PLoS Biol       Date:  2009-02-10       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.